United States Biotechnology & Medical Research

Decibel Therapeutics Inc (DBTX)

Track

Track

Decibel Therapeutics Inc. has recorded no insider trading activity within the past three months. The most recent transactions occurred on January 3, 2022, involving planned sales by Anna Trask. Prior historical data shows various buying and selling patterns by corporate officers and institutional entities, though these events fall well outside the current reporting window.
Ticker: DBTX Exchange: NSM
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Decibel Therapeutics Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
275.53
Quantity 79,250 +12.4%
Value US$798,834
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
49.24
Quantity 73,435 +2.4%
Value US$3,990,790
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
369.55
Quantity 6,141 -7.4%
Value US$3,772,190
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
6.37
Quantity 4,913 -65.2%
Value US$31,293
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
8.34
Quantity 378 -4.8%
Value US$3,152
Trask Anna SEE REMARKS Officer
Transaction date
Planned sale
Price
8.31
Quantity 4,913 -38.3%
Value US$40,827
Trask Anna See Remarks Officer
Transaction date
Planned sale
Price
7.55
Quantity 5,364 -29.5%
Value US$40,481
0.8
Reid Laurence President and Chief Executive Executive Director
Transaction date
Purchase
Price
7.64
Quantity 10,000 +63.1%
Value US$76,400
0.5
Foy Matthew Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 150,000 +14.5%
Value US$2,700,000
2.3
GLAXOSMITHKLINE PLC Non-Executive Director
Transaction date
Purchase
Price
18.00
Quantity 150,000 +14.5%
Value US$2,700,000
3.0
Thompson Peter A. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 555,566 +169.5%
Value US$10,000,188
3.0
Thompson Peter A. Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,111,100 +40.7%
Value US$19,999,800
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 555,566 +169.5%
Value US$10,000,188
2.6
ORBIMED ADVISORS LLC Non-Executive Director Large shareholder
Transaction date
Purchase
Price
18.00
Quantity 1,111,100 +40.7%
Value US$19,999,800
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2022-01-04 2022-01-03 PlS Planned sale
Trask Anna

See Remarks

Officer
79,250 +12.4%
275.53
US$798,834 		79,250 +12.4% 275.53 US$798,834
2022-01-04 2022-01-03 PlS Planned sale
Trask Anna

See Remarks

Officer
73,435 +2.4%
49.24
US$3,990,790 		73,435 +2.4% 49.24 US$3,990,790
2021-12-06 2021-12-02 PlS Planned sale
Trask Anna

See Remarks

Officer
6,141 -7.4%
369.55
US$3,772,190 		6,141 -7.4% 369.55 US$3,772,190
2021-12-06 2021-12-02 PlS Planned sale
Trask Anna

See Remarks

Officer
4,913 -65.2%
6.37
US$31,293 		4,913 -65.2% 6.37 US$31,293
2021-11-04 2021-11-03 PlS Planned sale
Trask Anna

See Remarks

Officer
378 -4.8%
8.34
US$3,152 		378 -4.8% 8.34 US$3,152
2021-11-03 2021-11-02 PlS Planned sale
Trask Anna

SEE REMARKS

Officer
4,913 -38.3%
8.31
US$40,827 		4,913 -38.3% 8.31 US$40,827
2021-10-15 2021-10-14 PlS Planned sale
Trask Anna

See Remarks

Officer
5,364 -29.5%
7.55
US$40,481 		5,364 -29.5% 7.55 US$40,481
2021-09-17 2021-09-15 B Purchase
0.8
Reid Laurence

President and Chief Executive

Executive Director
10,000 +63.1%
7.64
US$76,400 		10,000 +63.1% 7.64 US$76,400
2021-02-19 2021-02-17 B Purchase
0.5
Foy Matthew
Non-Executive Director Large shareholder
150,000 +14.5%
18.00
US$2,700,000 		150,000 +14.5% 18.00 US$2,700,000
2021-02-19 2021-02-17 B Purchase
2.3
GLAXOSMITHKLINE PLC
Non-Executive Director
150,000 +14.5%
18.00
US$2,700,000 		150,000 +14.5% 18.00 US$2,700,000
2021-02-19 2021-02-17 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
555,566 +169.5%
18.00
US$10,000,188 		555,566 +169.5% 18.00 US$10,000,188
2021-02-19 2021-02-17 B Purchase
3.0
Thompson Peter A.
Non-Executive Director Large shareholder
1,111,100 +40.7%
18.00
US$19,999,800 		1,111,100 +40.7% 18.00 US$19,999,800
2021-02-19 2021-02-17 B Purchase
3.2
Casdin Partners Master Fund, L.P.
Large shareholder
575,000 +105.2%
18.00
US$10,350,000 		575,000 +105.2% 18.00 US$10,350,000
2021-02-19 2021-02-17 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
555,566 +169.5%
18.00
US$10,000,188 		555,566 +169.5% 18.00 US$10,000,188
2021-02-19 2021-02-17 B Purchase
2.6
ORBIMED ADVISORS LLC
Non-Executive Director Large shareholder
1,111,100 +40.7%
18.00
US$19,999,800 		1,111,100 +40.7% 18.00 US$19,999,800
Explore more

More insider trading research around Decibel Therapeutics Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America